87 related articles for article (PubMed ID: 24602916)
1. Masitinib mesylate does not enhance sensitivity to radiation in three feline injection-site sarcoma cell lines under normal growth conditions.
Turek M; Gogal R; Saba C; Vandenplas ML; Hill J; Feldhausser B; Lawrence J
Res Vet Sci; 2014 Apr; 96(2):304-7. PubMed ID: 24602916
[TBL] [Abstract][Full Text] [Related]
2. Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
Lawrence J; Saba C; Gogal R; Lamberth O; Vandenplas ML; Hurley DJ; Dubreuil P; Hermine O; Dobbin K; Turek M
Vet Comp Oncol; 2012 Jun; 10(2):143-54. PubMed ID: 22236016
[TBL] [Abstract][Full Text] [Related]
3. Influence of different cell storage/culture conditions on spontaneous proliferation and level of tyrosine kinase receptor inhibition in two feline injection-site sarcoma cell lines.
Feldhaeusser BR; Turek M; Lawrence J; Cornell K; Gogal RM
J Immunoassay Immunochem; 2013; 34(3):266-82. PubMed ID: 23656247
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
Fahey CE; Milner RJ; Kow K; Bacon NJ; Salute ME
Anticancer Drugs; 2013 Jun; 24(5):519-26. PubMed ID: 23466652
[TBL] [Abstract][Full Text] [Related]
5. Gold nanoparticles enhance radiation sensitization and suppress colony formation in a feline injection site sarcoma cell line, in vitro.
Benton JZ; Williams RJ; Patel A; Meichner K; Tarigo J; Nagata K; Pethel TD; Gogal RM
Res Vet Sci; 2018 Apr; 117():104-110. PubMed ID: 29220723
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE; Milner RJ; Kow K; Salute ME
Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
[TBL] [Abstract][Full Text] [Related]
7. Safety of masitinib mesylate in healthy cats.
Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
[TBL] [Abstract][Full Text] [Related]
8. Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Thamm DH; Rose B; Kow K; Humbert M; Mansfield CD; Moussy A; Hermine O; Dubreuil P
Vet J; 2012 Jan; 191(1):131-4. PubMed ID: 21333567
[TBL] [Abstract][Full Text] [Related]
9. Changes in γ-H2AX expression in irradiated feline sarcoma cells: an indicator of double strand DNA breaks.
Lawrence J; Karpuzoglu E; Vance A; Vandenplas M; Saba C; Turek M; Gogal RM
Res Vet Sci; 2013 Jun; 94(3):545-8. PubMed ID: 23375429
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
Lee-Fowler TM; Guntur V; Dodam J; Cohn LA; DeClue AE; Reinero CR
Int Arch Allergy Immunol; 2012; 158(4):369-74. PubMed ID: 22487554
[TBL] [Abstract][Full Text] [Related]
11. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
12. Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro.
Rathore K; Alexander M; Cekanova M
Transl Res; 2014 Aug; 164(2):158-68. PubMed ID: 24631063
[TBL] [Abstract][Full Text] [Related]
13. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
[TBL] [Abstract][Full Text] [Related]
15. Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Zandvliet M; Teske E; Chapuis T; Fink-Gremmels J; Schrickx JA
J Vet Pharmacol Ther; 2013 Dec; 36(6):583-7. PubMed ID: 23363222
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative effect of metformin on a feline injection site sarcoma cell line independent of Mtor inhibition.
Pierro J; Saba C; McLean K; Williams R; Karpuzoglu E; Prater R; Hoover K; Gogal R
Res Vet Sci; 2017 Oct; 114():74-79. PubMed ID: 28319830
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy for treatment of injection-site sarcomas in cats: 11 cases (2008-2012).
Nolan MW; Griffin LR; Custis JT; LaRue SM
J Am Vet Med Assoc; 2013 Aug; 243(4):526-31. PubMed ID: 23902446
[TBL] [Abstract][Full Text] [Related]
18. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of doxorubicin and etoposide against a feline injection site sarcoma cell line.
Hill J; Lawrence J; Saba C; Turek M; Feldhaeusser B; Coutermarsh-Ott S; Barber J; Smith J; Gogal R
Res Vet Sci; 2014 Oct; 97(2):348-56. PubMed ID: 25085537
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
